ClinicalTrials.gg
TerminatedNCT00102791ASSERTUpdated Mar 27, 2008

A Stratified Sickle Event Randomized Trial (ASSERT)

A Phase 3 interventional study of ICA-17043 in Sickle Cell Disease, sponsored by Icagen. Terminated at 49 sites in 6 countries. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2008-03-27.

Sponsored by Icagen · Phase 3, Interventional, and Treatment

Why this study was terminated
Because of the low probability of achieving the primary endpoint.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
297
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
30th of 559
297 · median 31
Started
2005
with 19 others
Phase 3
50 of 733
10 open now
Registered
31st of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 30th largest by enrollment of the 559 interventional ones that give a count, is one of 20 that started in 2005, is one of 50 in phase 3, and was the 31st registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effects of ICA-17043 to placebo with or without hydroxyurea (an oral drug used for treatment of sickle cell disease) in patients with sickle cell disease who have had 2 or more acute sickle-related painful crises requiring a visit to a medical facility within the past 12 months.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Sickle Cell Anemia
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 16 to 65 years of age (inclusive)
  • Male or female (not capable of becoming pregnant or using appropriate )
  • Medical history of sickle cell disease
  • Have a history of at least two or more acute sickle-related painful crises requiring a visit to a medical facility within the preceding 12 months

Exclusion criteria

Exclusion Criteria:

  • \<4 or >11 g/dL
  • On a chronic transfusion program
  • Has significant active and poorly controlled (unstable) cardiovascular, neurologic, endocrine, hepatic, or renal disorders clearly unrelated to sickle cell disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
297 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Sickle Cell Crisis Rate

    Time frame: 52 weeks

Secondary outcomes

  1. Time to First, Second, and Third Crisis

    Time frame: 52 Weeks

  2. Maximum Crisis Morbidity Ranking

    Time frame: 52 Weeks

  3. Efficacy Related Laboratory Parameters

    Time frame: 52 Weeks

  4. Quality of Life

    Time frame: 52 Weeks

  5. Health Economics

    Time frame: 52 Weeks

07

Study locations

49 sites
  • Mobile, Alabama, United States
  • Little Rock, Arkansas, United States
  • Davis, California, United States
  • Los Angeles, California, United States
  • Oakland, California, United States
  • Denver, Colorado, United States
  • Hartford, Connecticut, United States
  • Washington, District of Columbia, United States
  • Holly Hill, Florida, United States
  • Hollywood, Florida, United States
  • Jacksonville, Florida, United States
  • Augusta, Georgia, United States
  • Savannah, Georgia, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • New Orleans, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Jackson, Mississippi, United States
  • Kansas City, Missouri, United States
  • Las Vegas, Nevada, United States
  • Hackensack, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Newark, New Jersey, United States
  • Bronx, New York, United States
  • Brooklyn, New York, United States
  • Chapel Hill, North Carolina, United States
  • Durham, North Carolina, United States
  • Greenville, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Memphis, Tennessee, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Richmond, Virginia, United States
  • Porto Alegre, Brazil
  • Rio de Janeiro, Brazil
  • Sao Paulo, Brazil
  • Creteil, France
  • Kingston, Jamaica
  • Port of Spain, Trinidad and Tobago
  • London, United Kingdom
08

References and documents

Publications

  • Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood. 2003 Mar 15;101(6):2412-8. doi: 10.1182/blood-2002-05-1433. Epub 2002 Nov 14. PubMed 12433690 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2005
First posted
Feb 2, 2005
Start
Feb 2005
CompletionActual
Jun 2007
Last update
Mar 27, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00102791
Lead sponsor
Icagen
First posted
Feb 2, 2005
Start date
Feb 2005
Completion
Jun 2007
Last update
Mar 27, 2008

Study contacts

Jonathan W Stocker, Ph.D.
study director · Icagen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Senicapoc

Start the discussion